Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects　― A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial ―-Reference-Cited by-同舟云学术

Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects　― A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial ―

Published:2021-10-25 Issue:11 Volume:85 Page:2063-2070
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Keech Anthony C.¹,Oyama Kazuma²,Sever Peter S.³,Tang Minao²,Murphy Sabina A.²,Hirayama Atsushi⁴,Lu Chen⁵,Tay Leslie⁶,Deedwania Prakash C.⁷,Siu Chung-Wah⁸,Lira Pineda Armando⁵,Choi Donghoon⁹,Charng Min-Ji¹⁰,Amerena John¹¹,Wan Ahmad Wan Azman¹²,Chopra Vijay K.¹³,Pedersen Terje R.¹⁴,Giugliano Robert P.²,Sabatine Marc S.²,

Affiliation:

1. National Health and Medical Research Council Clinical Trials Centre, Sydney Medical School, University of Sydney

2. TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School

3. International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London

4. Division of Cardiology, Department of Medicine, Nihon University School of Medicine

5. Amgen

6. Cardiology Department, Changi General Hospital

7. University of California San Francisco School of Medicine

8. Cardiology Division, Department of Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong SAR

9. Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine

10. Division of Cardiology, Taipei Veterans General Hospital

11. Geelong Cardiology Research Unit, Barwon Health

12. Cardiology Department, University Malaya Medical Center

13. Department of Cardiology, Max Super Speciality Hospital

14. Medical Faculty, Oslo University Hospital Aker

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/circj/85/11/85_CJ-20-1051/_pdf

Reference19 articles.

1. 1. Chidambaran V, Ngamprasertwong P, Vinks AA, Sadhasivam S. Pharmacogenetics and anesthetic drugs. Curr Clin Pharmacol 2012; 7: 78–101.

2. 2. Shin J, Johnson JA. Pharmacogenetics of beta-blockers. Pharmacotherapy 2007; 27: 874–887.

3. 3. Wang Y, Yan BP, Tomlinson B, Lee VW. Is lipid goal one-size-fits-all: A review of evidence for recommended low-density lipoprotein treatment targets in Asian patients. Eur J Prev Cardiol 2019; 26: 1496–1506.

4. 4. Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol 2007; 99: 410–414.

5. 5. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–1278.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimal Target Low-density Lipoprotein Level for Reducing the Risk of Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis;Korean Journal of Clinical Pharmacy;2023-12-31

2. Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China;Cost Effectiveness and Resource Allocation;2023-12-01

3. Epidemiology of Diabetes and Atherosclerotic Cardiovascular Disease Among Asian American Adults: Implications, Management, and Future Directions: A Scientific Statement From the American Heart Association;Circulation;2023-07-04

4. The PACMAN-AMI trial: a revolution in the treatment of acute coronary syndromes;European Heart Journal Supplements;2023-04-26

5. PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells;International Journal of Molecular Sciences;2023-03-07